CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.08
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.83

30 Nov
2023

-0.030

OPEN

$0.86

-3.49%

HIGH

$0.86

34,133

LOW

$0.83

TARGET
$0.85 2.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
CLV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 3.7 5.0 xxx
DPS (cps) xxx 1.5 N/A xxx
EPS Growth xxx - 13.3% 34.4% xxx
DPS Growth xxx 0.0% N/A xxx
PE Ratio xxx N/A 17.2 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 40.3% 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.84%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.74

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 30/10 - ex-div 0.75c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx3.7
DPS All xxxxxxxxxxxxxxx1.5
Sales/Revenue xxxxxxxxxxxxxxx79.9 M
Book Value Per Share xxxxxxxxxxxxxxx40.2
Net Operating Cash Flow xxxxxxxxxxxxxxx6.7 M
Net Profit Margin xxxxxxxxxxxxxxx7.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx9.53 %
Return on Invested Capital xxxxxxxxxxxxxxx8.27 %
Return on Assets xxxxxxxxxxxxxxx7.02 %
Return on Equity xxxxxxxxxxxxxxx9.53 %
Return on Total Capital xxxxxxxxxxxxxxx12.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx10 M
Total Debt xxxxxxxxxxxxxxx12 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx9 M
Price To Book Value xxxxxxxxxxxxxxx2.71

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx56 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxxxxx12 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

24/11/2023

3

Neutral

$0.85

2.41%

The infant milk formula market in China has remained challenging, notes UBS, after reviewing an AGM trading update by Clover.

Management now expects FY24 revenue of around $70m, a -14% miss compared to the broker's forecast. As a result of this disappointment, the analyst lowers the Clover target to 85c from $1.10.

The Neutral rating is unchanged due to low near-term market visibility, explains UBS.

The analyst cites two potential positives for the stock price: the upcoming 2024 Year of the Dragon, which traditionally signifies an increase in Chinese birth rates; and major competitor BASF has discontinued its docosahexaenoic acid (DHA) product.

FORECAST
UBS forecasts a full year FY24 EPS of 5.00 cents.
Access Stockbroker Research History >

CLV STOCK CHART

FNArena News on CLV

1
Australian Broker Call *Extra* Edition – Nov 29, 2023

Nov 29 2023 - Daily Market Reports
2
FNArena Corporate Results Monitor – 29-09-2023

Sep 29 2023 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 17-03-23

Mar 20 2023 - Weekly Reports
4
FNArena Corporate Results Monitor – 17-03-2023

Mar 17 2023 - Australia
5
FNArena Corporate Results Monitor – 26-09-2022

Sep 26 2022 - Australia

Latest Health & Nutrition News

1
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
2
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
3
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
4
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
5
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
6
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
7
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
8
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
9
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
10
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia